Ovid Therapeutics (OVID) Enterprise Value (2016 - 2026)
Ovid Therapeutics (OVID) posted Enterprise Value of -$155.5 million for Q1 2026, down 123.34% on a QoQ basis from -$69.6 million in Q4 2025, and down 281.32% year-over-year from $85.8 million in Q1 2025.
Ovid Therapeutics (OVID) Enterprise Value (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Enterprise Value history runs 11 years deep, the most recent figure standing at -$155.5 million for Q1 2026.
- Quarterly Enterprise Value fell 281.32% year-over-year to -$155.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$155.5 million (down 281.32% YoY) and the FY2025 annual result came in at -$69.6 million, down 32.5% from the prior year.
- Enterprise Value was -$155.5 million for Q1 2026 at Ovid Therapeutics, down from -$69.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$25.5 million in Q3 2025 and bottomed at -$168.6 million in Q1 2022.
- A 5-year average of -$94.0 million and a median of -$88.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 58.19% — and 2026, when it plunged 281.32%.
- Ovid Therapeutics' Enterprise Value stood at -$126.1 million in 2022, then increased by 18.25% to -$103.1 million in 2023, then jumped by 49.04% to -$52.6 million in 2024, then tumbled by 32.5% to -$69.6 million in 2025, then plunged by 123.34% to -$155.5 million in 2026.
- Business Quant data shows OVID's Enterprise Value at -$155.5 million in Q1 2026, -$69.6 million in Q4 2025, and -$25.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Ovid Therapeutics | 120.91 Mn | -34.61 Mn | - | -155.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155.52 Mn |
| Dec 31, 2025 | -69.64 Mn |
| Sep 30, 2025 | -25.48 Mn |
| Jun 30, 2025 | -38.35 Mn |
| Mar 31, 2025 | -40.79 Mn |
| Dec 31, 2024 | -52.55 Mn |
| Sep 30, 2024 | -60.93 Mn |
| Jun 30, 2024 | -76.97 Mn |
| Mar 31, 2024 | -88.94 Mn |
| Dec 31, 2023 | -103.13 Mn |
| Sep 30, 2023 | -87.07 Mn |
| Jun 30, 2023 | -96.52 Mn |
| Mar 31, 2023 | -117.72 Mn |
| Dec 31, 2022 | -126.15 Mn |
| Sep 30, 2022 | -137.86 Mn |
| Jun 30, 2022 | -152.37 Mn |
| Mar 31, 2022 | -168.60 Mn |
| Dec 31, 2021 | -187.80 Mn |
| Sep 30, 2021 | -201.80 Mn |
| Jun 30, 2021 | -212.20 Mn |